Geneva, April 28 -- International Clinical Trials Registry received information related to the study (ChiCTR2600122495) titled 'Exploration study on the neurobiological mechanism of Shugan Jieyu Capsules in the treatment of post-stroke depression' on April 14.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Guangdong Provincial Hospital of Chinese Medicine
Condition:
Post-stroke depression
Intervention:
PSD group(Intervention group):Patients took Shugan Jieyu Capsules orally (2 capsules per dose, twice a day) for a duration of 12 weeks. At the same time, all patients received standard secondary stroke prevention and rehabilitation treatment.
Recruitment Status: Not Recruiting
Phase: 4
Date of First ...